Line Uhrenholt

10PUBLICATIONS
30CO-AUTHORS
Solid tumoursAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Rheumatology and arthritisToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 26, 2026
The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study.

|Jul 23, 2024
Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial.

Line Uhrenholt, Mads E R Sørensen, Karen B Lauridsen

|Jul 09, 2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.

Mikkel Østergaard, Ronald F van Vollenhoven, Anna Rudin

|Jun 05, 2023
Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial.

Line Uhrenholt, Kirsten Duch, Robin Christensen

|Feb 06, 2023
Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.

L Uhrenholt, R Christensen, L Dreyer

|Apr 01, 2022
Isolation in patients with inflammatory rheumatic diseases during COVID-19 pandemic compared to healthy individuals: a questionnaire survey.

Tobias Eschricht Eriksen, Wilfred K H Dinesen, Line Uhrenholt

Pageof 2

Frequent Collaborators

5 joint publications

Lene Wohlfahrt Dreyer

5 joint publications

Kirsten S Duch

5 joint publications

Salome Kristensen

4 joint publications

Peter C Taylor